It would be an understatement to say that pharmaceutical company Novavax Inc. did not have a great 2019.
The Gaithersburg company saw its ResVax vaccine for respiratory syncytial virus fall short in yet another late-stage clinical trial — its second such miss in three years — causing its stock price to plummet and, at one point, earning it a delisting threat from Nasdaq. The Food and Drug Administration proceeded to order up another late-stage clinical trial before it would consider ResVax,…